Cost-effectiveness in managing skeletal related events in breast cancer: a strategy of less-intense dosing schedule of bone modifying agents

Sri Harsha Tella, Anuhya Kommalapati, Ryan K. Singhi


The introduction of bone-modifying agents (BMA) or skeletal protective agents in the mid 1990’s into oncology armamentarium has revolutionized the management of skeletal related events (SREs) in cancer patients with established bone metastases. The health and financial burden of SREs are significantly reduced with the use of adjuvant BMAs.